ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2335

Defining a Basket Population for ANA+ Arthritis Trials

Jack Arnold1, Md Yuzaiful Md Yusof1, Lucy Carter2, Zoe Wigston1 and Ed Vital1, 1University of Leeds, Leeds, United Kingdom, 2University of Leeds, Hartlepool, United Kingdom

Meeting: ACR Convergence 2023

Keywords: Myositis, Sjögren's syndrome, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2326–2351) SLE – Treatment Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Musculoskeletal (MSK) manifestations are common in systemic lupus erythematosus (SLE) and other ANA-associated rheumatic musculoskeletal diseases (ANA-RMDs). Presently clinical trials recruit patients from individual diagnoses. Recruitment is often difficult, effect sizes are small and licensed therapies are only available to patients with the most common ANA-RMD, SLE.

Objectives:
1. To compare the symptom impact and immunophenotype of arthritis associated with a range of ANA-associated autoimmune diseases
2. To explore alternative classifications of the spectrum of ANA-associated arthritis to define basket populations for trials
3. To validate the MSK-BILAG across multiple diagnoses

Methods: We used analysis of flow cytometry for major subsets, gene expression (signatures for interferon, plasma blast, neutrophil, myeloid inflammation and erythropoiesis) and patient reported data from a mixed cohort of ANA-associated autoimmune diseases. 215 patients with MSK symptoms were included, 90 with SLE and 125 with an another diagnosis (UCTD, pSS, IM, MCTD and SSc).

The implications of legacy diagnosis membership were compared using QoL measures (SF36, EQ5D-5L, Patient VAS, ICECAP-A, FACIT-F, WPAI and ICECAP-A. Gaussian mixture modelling was used to explore alternative classifications more suitable for basket trials. The association of BILAG-MSK with physician VAS was tested in SLE and the non-SLE group.

Results: Legacy diagnosis was a poor indicator of the patient experience with Kruskal Wallis testing revealing only 2 significant differences (EQ5D Mobility and EQ5D-5l index domains) between diagnoses. Flow cytometric and gene expression data showed no significant differences between legacy diagnoses.

Better predictors of the patient experience were chromatin antibody positivity and non-European ancestry which were associated with worse EQ5D-5l index scores (P < 0.05 in both).

Preliminary gaussian mixture modelling analysis of this population based on variables identified as important within the principle component analysis identified 4 clusters. A biologically active MSK symptom dominant cluster (n=140), a biologically active non MSK symptom dominant cluster (n=43), a biologically and symptom quiescent cluster (n= 24) and a biologically and symptom quiescent cluster (n=65).

The application of the BILAG-MSK domain across ANA-RMDs correlated well with the Physician General Assessment scores of MSK disease activity suggesting it may be reasonable to apply this measure in any future basket trial.

Conclusion: Inflammatory arthritis is similar in both clinical impact and immune phenotype across ANA-associated RMDs, suggesting similar benefits of therapy for this feature within each disease. Machine learning reveals an alternative basket of patients suitable for clinical trials who have clinical synovitis, high symptom burden and consistently increased markers of immune activation, and a mixture of legacy diagnoses, who are more numerous than MSK SLE alone. A further smaller basket of patients have high symptom burden but little evidence of active inflammation.


Disclosures: J. Arnold: None; M. Md Yusof: Novartis, 6, Roche, 6, UCB, 1; L. Carter: UCB, 1; Z. Wigston: None; E. Vital: F. Hoffmann-La Roche Ltd, 2, Genentech, Inc., 2, Sandoz, 5.

To cite this abstract in AMA style:

Arnold J, Md Yusof M, Carter L, Wigston Z, Vital E. Defining a Basket Population for ANA+ Arthritis Trials [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/defining-a-basket-population-for-ana-arthritis-trials/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/defining-a-basket-population-for-ana-arthritis-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology